Latest News

12345678910
MoonLake Immunotherapeutics Data Shows Phase 2 Success For Chronic Back Painbenzinga.com
MoonLake stock rises after Phase 2 trial shows 81% response in chronic back pain study, boosting investor confidence Monday.
Via Benzinga · February 23, 2026
TARIFF CHAOS: Is Silver Going To $92 Or $50? (Exact Chart Targets)talkmarkets.com
Via Talk Markets · February 23, 2026
Insights Ahead: Xometry's Quarterly Earningsbenzinga.com
Via Benzinga · February 23, 2026
Hims & Hers In Focus Before Q4 Earnings Releasebenzinga.com
Hims & Hers Health is in the spotlight Monday as the company prepares to report fourth-quarter earnings after the market closes.
Via Benzinga · February 23, 2026
A Peek at Zeta Global Holdings's Future Earningsbenzinga.com
Via Benzinga · February 23, 2026
DJT Stock Draws Bearish Retail Buzz On Tariff Turmoil And Supreme Court Rulingstocktwits.com
On Friday, the U.S. Supreme Court struck down President Donald Trump’s tariffs, citing that he exceeded his authority by invoking an emergency-powers law.
Via Stocktwits · February 23, 2026
Uncovering Potential: Westlake's Earnings Previewbenzinga.com
Via Benzinga · February 23, 2026
Turning Healthy Eating Trends into Scalable Business Opportunitiestalkmarkets.com
Via Talk Markets · February 23, 2026
Insights Ahead: Constellation Energy's Quarterly Earningsbenzinga.com
Via Benzinga · February 23, 2026
Beaten-Down Figma Shares Rebound on Strong Growth Outlook. Is the Stock a Buy?fool.com
The stock is still trading below its 2025 IPO price.
Via The Motley Fool · February 23, 2026
4 Things You Need to Know Before Allergy Season
(BPT) - As spring draws near, allergy season follows close behind. While blooming flowers and budding trees may be welcome, they can also bring allergens that trigger sneezing, congestion and itchy, watery eyes for millions. Allergies are nothing to sneeze at: they currently affect approximately 30% of adults and 40% of children in the U.S., making them an ongoing struggle for many.
Via Brandpoint · February 23, 2026
A Preview Of Coca-Cola Femsa's Earningsbenzinga.com
Via Benzinga · February 23, 2026
$1000 Invested In Intuit 15 Years Ago Would Be Worth This Much Todaybenzinga.com
Via Benzinga · February 23, 2026
Uncovering Potential: Home Depot's Earnings Previewbenzinga.com
Via Benzinga · February 23, 2026
What to Expect from Bank of Nova Scotia's Earningsbenzinga.com
Via Benzinga · February 23, 2026
MercadoLibre's Earnings Outlookbenzinga.com
Via Benzinga · February 23, 2026
Earnings Outlook For EOG Resourcesbenzinga.com
Via Benzinga · February 23, 2026
What 4 Analyst Ratings Have To Say About Spectrum Brands Holdingsbenzinga.com
Via Benzinga · February 23, 2026
Assessing Blue Owl Technology: Insights From 4 Financial Analystsbenzinga.com
Via Benzinga · February 23, 2026
Beyond The Numbers: 11 Analysts Discuss Axsome Therapeutics Stockbenzinga.com
Via Benzinga · February 23, 2026
Exploring Realty Income's Earnings Expectationsbenzinga.com
Via Benzinga · February 23, 2026
Insights into Ferguson's Upcoming Earningsbenzinga.com
Via Benzinga · February 23, 2026
Where iRhythm Holdings Stands With Analystsbenzinga.com
Via Benzinga · February 23, 2026
How Do Investors Really Feel About Hewlett Packard Enterprise Co?benzinga.com
Via Benzinga · February 23, 2026
Assessing Imax: Insights From 9 Financial Analystsbenzinga.com
Via Benzinga · February 23, 2026
Looking Into Rackspace Technology Inc's Recent Short Interestbenzinga.com
Via Benzinga · February 23, 2026
What's Driving the Market Sentiment Around Ocular Therapeutix Inc?benzinga.com
Via Benzinga · February 23, 2026
Vanda Pharmaceuticals FDA Approval Dawns A New Era For Bipolar And Schizophrenia Treatmentbenzinga.com
Vanda shares rise after FDA approves Bysanti for bipolar I and schizophrenia, with launch planned for 2026.
Via Benzinga · February 23, 2026
What 4 Analyst Ratings Have To Say About Allegionbenzinga.com
Via Benzinga · February 23, 2026
Gold vs. Silver Showdown: Should You Buy SGDM or SIL ETF?fool.com
Explore how these miner ETFs differ in risk, cost, and portfolio makeup -- key factors for refining a precious metals strategy.
Via The Motley Fool · February 23, 2026
Nvidia May Have Dumped Arm Stock in Q4, But Should You Buy Shares Now?
With Nvidia dumping its entire stake in Arm Holdings, is this a red flag or a timely buying opportunity for investors?
Via Barchart.com · February 23, 2026
An Interesting Development On The Silver Charttalkmarkets.com
Via Talk Markets · February 23, 2026
Why Corporate Margins Are Staying High Despite Inflationbenzinga.com
Via Benzinga · February 23, 2026
CNX Resources Corp (NYSE:CNX) Shows Strong Technical Setup for a Potential Breakoutchartmill.com
Via Chartmill · February 23, 2026
How To Trade SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, TSLA Using Technical Analysisbenzinga.com
Via Benzinga · February 23, 2026
This Penny Stock Is Building a Strategic Silver Reserve. Should You Buy Shares Now to Bet on a Run in Silver Prices?
Hyperscale Data’s plan to stack up silver alongside a 600 BTC treasury worth $41 million turns GPUS stock into a leveraged way to bet on a silver run toward $150.
Via Barchart.com · February 23, 2026
3 New Stocks Billionaire Dan Loeb Is Betting on Now
Dan Loeb’s new stakes in Chipotle, Spotify, and Alibaba are a concentrated bet that markets have overshot on fear in three still‑profitable growth franchises, each with clear multi‑year earnings drivers.
Via Barchart.com · February 23, 2026
Molina Healthcare Stock Outlook: Is Wall Street Bullish or Bearish?
Are Wall Street analysts seeing a recovery in beaten-down stock Molina Healthcare?
Via Barchart.com · February 23, 2026
Market Analysis - Monday, Feb. 23talkmarkets.com
Via Talk Markets · February 23, 2026
MSCI Stock: Is Wall Street Bullish or Bearish?
Although MSCI has underperformed relative to the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.
Via Barchart.com · February 23, 2026
Nvidia Stock Is Stuck, But JPMorgan Anticipates Another 'Beat-And-Raise'benzinga.com
Nvidia stock has stalled, but JPMorgan expects another beat-and-raise as AI demand exceeds supply, backlog supports growth into 2027.
Via Benzinga · February 23, 2026
Domino's Pizza Rewards Investors With 15% Dividend Hike - Here's Whybenzinga.com
Domino's Pizza Inc. (NASDAQ: DPZ) reported Q4 fiscal 2025 results, raised its dividend, and added 392 stores worldwide.
Via Benzinga · February 23, 2026
Joe Rogan Says Regular People With Regular Jobs Scare The Sh*t Out Of Him. 'I Don't Want To Get Sucked Into Your Drone-Like Frequency'benzinga.com
Via Benzinga · February 23, 2026
IMG Wealth Sells $4 Million of First Trust Capital Strength ETFfool.com
First Trust Capital Strength ETF tracks U.S. companies with strong balance sheets and stable earnings for lower-volatility exposure.
Via The Motley Fool · February 23, 2026
Strategy Buys Bitcoin For The 100th Time, Even Amid Severe Bear Marketstocktwits.com
The company recently bought 592 Bitcoin for $39.8 million, following the sale of 297,940 Class A shares through its at-the-market program.
Via Stocktwits · February 23, 2026
Top 3 Materials Stocks That May Plunge This Monthbenzinga.com
Via Benzinga · February 23, 2026
Here's Why I'll Never Have More Than One Card With an Annual Feefool.com
The no-annual-fee card market has never been better. Here's why paying multiple annual fees often leaves you breaking even -- or worse.
Via The Motley Fool · February 23, 2026
Is It Time to Dump Your Shares of Tilray?​fool.com
Holding this stock has been a painful lesson about cutting your losses.
Via The Motley Fool · February 23, 2026
FDA Accepts Teva's New Long-Acting Schizophrenia Treatment Applicationbenzinga.com
FDA accepts Teva's application for the monthly schizophrenia injection TEV-749 as shares show mixed momentum signals.
Via Benzinga · February 23, 2026
Gilead Bets Big On Anito-Cel With $7.8 Billion Arcellx Dealinvestors.com
Gilead Sciences is buying Arcellx for $7.8 billion because it sees potential for more than $6 billion in sales for anito-cel by 2029. GILD stock slipped as ACLX soared.
Via Investor's Business Daily · February 23, 2026